{"id":"https://openalex.org/W4322769908","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-14","title":"Abstract P3-01-14: Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database","display_name":"Abstract P3-01-14: Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database","publication_year":2023,"publication_date":"2023-03-01","ids":{"openalex":"https://openalex.org/W4322769908","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-14"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs22-p3-01-14","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-14","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-01-14","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope Rugo","raw_affiliation_strings":["1University of California San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090463130","display_name":"Xianchen Liu","orcid":"https://orcid.org/0000-0003-0411-1050","observed_orcids":["https://orcid.org/0000-0003-0411-1050","https://orcid.org/0000-0002-4325-2545"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xianchen Liu","raw_affiliation_strings":["2Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023195809","display_name":"Benjamin C. Li","orcid":"https://orcid.org/0000-0002-1783-7013","observed_orcids":["https://orcid.org/0000-0002-1783-7013","https://orcid.org/0009-0005-1054-5228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Li","raw_affiliation_strings":["3Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042491180","display_name":"Lynn McRoy","orcid":"https://orcid.org/0000-0002-0986-5364","observed_orcids":["https://orcid.org/0000-0002-0986-5364"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lynn McRoy","raw_affiliation_strings":["4Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101442865","display_name":"Connie Chen","orcid":"https://orcid.org/0000-0001-5384-4707","observed_orcids":["https://orcid.org/0000-0001-5384-4707","https://orcid.org/0000-0002-5221-5711"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Connie Chen","raw_affiliation_strings":["5Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064168158","display_name":"Rachel M. Layman","orcid":"https://orcid.org/0000-0002-8663-0331","observed_orcids":["https://orcid.org/0000-0002-8663-0331"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel M. Layman","raw_affiliation_strings":["6The University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6The University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044108002","display_name":"Adam Brufsky","orcid":"https://orcid.org/0000-0001-8080-7960","observed_orcids":["https://orcid.org/0000-0001-8080-7960","https://orcid.org/0009-0006-2725-3579"]},"institutions":[{"id":"https://openalex.org/I4210098814","display_name":"UPMC Health System","ror":"https://ror.org/011htkb76","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam M. Brufsky","raw_affiliation_strings":["7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center","institution_ids":["https://openalex.org/I4210098814","https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"5_Supplement","first_page":"P3","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/aromatase-inhibitors","display_name":"aromatase inhibitors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8159999847412109},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.8679999709129333},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9620000123977661},{"id":"https://openalex.org/keywords/first-line-endocrine-therapy","display_name":"first-line endocrine therapy","score":0.8619999885559082},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.7630000114440918},{"id":"https://openalex.org/keywords/dosing-patterns","display_name":"dosing patterns","score":0.7329999804496765},{"id":"https://openalex.org/keywords/time-to-next-therapy","display_name":"time to next therapy","score":0.722000002861023},{"id":"https://openalex.org/keywords/time-to-chemotherapy","display_name":"time to chemotherapy","score":0.7239999771118164},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.4819999933242798},{"id":"https://openalex.org/keywords/flatiron-health","display_name":"Flatiron Health","score":0.7429999709129333},{"id":"https://openalex.org/keywords/electronic-health-records","display_name":"electronic health records","score":0.6660000085830688},{"id":"https://openalex.org/keywords/postmenopausal-patients","display_name":"postmenopausal patients","score":0.7289999723434448},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.4009999930858612}],"concepts":[{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.8477528691291809},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.762819230556488},{"id":"https://openalex.org/C2778504769","wikidata":"https://www.wikidata.org/wiki/Q3040305","display_name":"Aromatase inhibitor","level":5,"score":0.6951702833175659},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6110128164291382},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5566003322601318},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5136687159538269},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5068112015724182},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4565259516239166},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.43590104579925537},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.3381236493587494}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs22-p3-01-14","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-14","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-01-14","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2977725664","https://openalex.org/W4387599340","https://openalex.org/W4229067232","https://openalex.org/W2947775600","https://openalex.org/W3168203807","https://openalex.org/W4304190250","https://openalex.org/W4322769907","https://openalex.org/W2944585831","https://openalex.org/W7131290469","https://openalex.org/W4229023962"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"CDK4/6":[2],"inhibitor":[3,9,488,491],"in":[4,42,57,91,267,274,296,308,314,331,341,366,387,394,434,444,497],"combination":[5],"with":[6,23,233,237,305,319],"an":[7,486],"aromatase":[8,487,490],"(AI)":[10],"or":[11,112,126,156,182,255,460,489],"fulvestrant":[12],"as":[13,137,161],"initial":[14],"endocrine":[15],"therapy":[16,49,121,154,285,420,441,450,459],"are":[17],"standard":[18],"of":[19,69,120,163,168,173,184,199,220,312,417,440,458,483,504],"care":[20],"for":[21,54,376,407,412,493],"patients":[22,43,90,282,313,398,418],"HR+/HER2\u2013":[24,55,413],"advanced/metastatic":[25],"breast":[26,495],"cancer":[27,80,89,496],"(mBC).":[28],"This":[29,64],"analysis":[30,68],"describes":[31],"treatment":[32,41,133,169,206,391,411,481],"patterns":[33,36,134,392,482],"including":[34],"dosing":[35,320],"and":[37,97,104,140,209,223,235,271,293,336,361,442],"time":[38,151,164,454],"to":[39,51,122,152,170,194,218,437,448,455],"subsequent":[40,153],"receiving":[44,283],"first":[45,408],"line":[46,172,409,439,457],"Palbociclib":[47,484],"(PB)+AI":[48],"compared":[50,447],"AI":[52,113,276,343,368,449],"alone,":[53],"mBC":[56,102,397],"the":[58,92,147,166,196,228,268,275,280,332,342,367,377,422,435,445,498,505],"US":[59,402],"routine":[60],"clinical":[61,224,403],"setting.":[62],"Methods:":[63],"was":[65,159,241,264,286,326,354],"a":[66,395],"retrospective":[67],"Flatiron":[70,499],"Health\u2019s":[71],"nationwide":[72],"longitudinal":[73],"electronic":[74],"health":[75],"records":[76,145],"from":[77,118,143,165,177,399],"over":[78],"280":[79],"clinics":[81],"representing":[82],"more":[83],"than":[84],"3":[85],"million":[86],"actively":[87],"treated":[88],"US.":[93],"Between":[94],"February":[95],"2015":[96],"March":[98],"2020,":[99,124],"2888":[100,229],"postmenopausal":[101],"women":[103],"men":[105],"aged":[106],"\u226518":[107],"years":[108],"started":[109,287],"first-line":[110],"PB+AI":[111,200,234,269,359,410,446],"therapy.":[114],"Patients":[115],"were":[116,135,192,216,245,380],"followed":[117],"start":[119,167],"September":[123],"death,":[125],"last":[127,180],"visit,":[128,181],"whichever":[129,186],"came":[130,187],"first.":[131,188],"PB":[132,303,333],"captured":[136],"starting":[138,316],"dose":[139,141,306,317,425],"adjustments":[142],"medical":[144],"during":[146],"observation":[148],"period.":[149],"Comparative":[150],"(TTNT)":[155],"chemotherapy":[157,443,461],"(TTC)":[158],"defined":[160],"length":[162],"next":[171,438,456],"anticancer":[174],"therapy/chemotherapy,":[175],"death":[176],"any":[178],"cause,":[179],"end":[183],"study,":[185],"Cox":[189],"proportional-hazards":[190],"models":[191],"used":[193,217],"estimate":[195],"relative":[197],"effectiveness":[198],"vs":[201],"AI.":[202],"Stabilized":[203],"inverse":[204],"probability":[205],"weighting":[207],"(sIPTW)":[208],"propensity":[210],"score":[211],"matching":[212],"(PSM)":[213],"statistical":[214],"methods":[215],"balance":[219],"baseline":[221],"demographics":[222],"characteristics.":[225],"Results:":[226],"Of":[227,279],"eligible":[230],"pts":[231],"(1324":[232],"1564":[236],"AI),":[238],"median":[239,324,352],"age":[240],"70.0":[242],"years,":[243],"67.8%":[244],"white,":[246],"34.8%":[247],"had":[248,253,259],"de":[249],"novo":[250],"mBC,":[251],"29.4%":[252],"lung":[254],"liver":[256],"involvement,":[257],"38.7%":[258],"bone-only":[260],"disease.":[261],"Median":[262,453],"follow-up":[263],"25.0":[265],"months":[266,273,328,338,356,363],"arm":[270],"23.3":[272],"alone":[277,492],"arm.":[278,451],"1342":[281],"PB,":[284],"at":[288,421],"125":[289,423],"mg,":[290,292],"100":[291],"75":[294],"mg/day":[295],"83.8%,":[297],"10.9%,":[298],"3.6%,":[299],"respectively":[300],"(1.7%":[301],"undocumented":[302],"dose)":[304],"changes":[307],"41.1%,":[309],"36.8%,":[310],"31.3%":[311],"each":[315],"category":[318],"information.":[321],"After":[322,350],"sIPTW":[323,351],"TTNT":[325],"18.4":[327],"(95%CI:":[329,339,346,357,364,371],"16.3-20.3)":[330],"+AI":[334],"group":[335,360],"8.3":[337],"7.2-10.0)":[340],"group;":[344,369],"HR=0.56":[345],"0.51-0.62),":[347],"p<":[348,373],"0.0001.":[349,374],"TTC":[353],"37.4":[355],"33.7-40.7)":[358],"29.2":[362],"26.8-33.5)":[365],"HR=0.77":[370],"0.69-0.86),":[372],"Results":[375],"PSM":[378],"analyses":[379,393,429],"similar.":[381],"The":[382,415],"table":[383],"presents":[384],"full":[385],"results":[386],"detail.":[388],"Conclusions:":[389],"These":[390],"heterogeneous":[396],"real":[400],"world":[401],"practice,":[404],"provide":[405],"support":[406],"mBC.":[414],"majority":[416],"initiated":[419],"mg/daily":[424],"(84%).":[426],"Importantly,":[427],"these":[428],"also":[430],"report":[431],"meaningful":[432],"differences":[433],"delay":[436],"Table.":[452],"Citation":[462],"Format:":[463],"Hope":[464],"Rugo,":[465],"Xianchen":[466],"Liu,":[467],"Benjamin":[468],"Li,":[469],"Lynn":[470],"McRoy,":[471],"Connie":[472],"Chen,":[473],"Rachel":[474],"M.":[475,478],"Layman,":[476],"Adam":[477],"Brufsky.":[479],"Real-world":[480],"plus":[485],"metastatic":[494],"database":[500],"[abstract].":[501],"In:":[502],"Proceedings":[503],"2022":[506,512],"San":[507,515],"Antonio":[508],"Breast":[509],"Cancer":[510,521],"Symposium;":[511],"Dec":[513],"6-10;":[514],"Antonio,":[516],"TX.":[517],"Philadelphia":[518],"(PA):":[519],"AACR;":[520],"Res":[522],"2023;83(5":[523],"Suppl):Abstract":[524],"nr":[525],"P3-01-14.":[526]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-03-03T00:00:00"}